Oct 04, 2022
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Oct 03, 2022
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
Sep 26, 2022
Immutep to Participate in Two Upcoming Investor Conferences
Sep 22, 2022
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Sep 13, 2022
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
